Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial

by COMPASS Investigators, Alings, M, Anand, SS, Avezum, A, Bhatt, DL, Bosch, J, Branch, KRH, Bruns, NC, Commerford, PJ, Connolly, SJ, Dagenais, GR, Dans, A, Diaz, R, Dyal, L, Eikelboom, JW, Ertl, G, Felix, C, Fox, KAA, Guzik, T, Hart, RG, Hori, M, Kakkar, A, Keltai, M, Kim, JH, Lanas, F, Leong, D, Lewis, BS, Liang, Y, Lonn, EM, Lopez-Jaramillo, P, Maggioni, AP, Metsarinne, K, Moayyedi, P, Muehlhofer, E, ODonnell, M, Parkhomenko, AN, Piegas, LS, Pogosova, N, Probstfield, J, Ryden, L, Shestakovska, O, Steg, PG, Stork, S, Tonkin, AM, Torp-Pedersen, C, Verhamme, PB, Vinereanu, D, Widimsky, P, Yusoff, K, Yusuf, S, Zhu, J
Published 2019